




BrainsWay OCD is designed to target the dorsomedial PFC including the anterior cingulate (ACC)


In a large scale double-blinded multicenter RCT

>1 in 3 patients achieved response



- Patients with inadequate relief from medications/CBT
- Response – > 30% reduction in Y-BOCS ; Partial response > 20% reduction in Y-BOCS.
- Treatment is 5 sessions per week for 6 weeks.
- A tailored provocation protocol during each session.

6.7 mean change in Y-BOCS achieved in just 6 weeks



Mean change in Y-BOCS from baseline in BrainsWay multi center trial

Mean change in Y-BOCS from baseline using SSRI medications* for OCD

A de novo request has been submitted to the FDA for permission to market BrainsWay for the treatment of Obsessive Compulsive Disorder (OCD), and is currently pending.



*Data on SSRI medications based on meta-analysis (Soomra et al, 2008)